

**Tillotts Pharma Transfers of Value in 2018 to Italian Healthcare Professionals and Healthcare Organisations**

Date of publication: June 2019

	Full Name  (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered  (Art. 3)	Country of Principal Practice  (Schedule 1)	Principal Practice Address  (Art. 3)	Unique country local identifier OPTIONAL  (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		Transfer of Value re Research & Development as defined (Art. 3.04)	Total OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the contract, including travel & accommodation relevant to the contract			
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
	Prof. Dr. Silvio Danese	Rozzano	Italy	Via Alessandro Manzoni, 56, 20089 Rozzano, Milano, Italy		N/A	N/A			3'000 €		N/A	N/A	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.2						N/A	N/A	0	0	6'500 €	175 €	N/A	N/A
	Number of Recipients (named list, where appropriate) - Art. 3.2						N/A	N/A	N/A	N/A	2	1	N/A	N/A
	% of totaltransfers of value to individual HCPs - Art. 3.2.						N/A	N/A	%	%	66.70%	50%	N/A	N/A
	% on total of Recipients - Art. 3.02						N/A	N/A	%	%	66.70%	100%	N/A	N/A
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
												N/A		
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.2						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	N/A	N/A
	Number of Recipients (named list, where appropriate) - Art. 3.2						N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
% of totaltransfers of value to individual HCOs - Art. 3.2.						%	%	%	%	%	%	N/A	N/A	
AGGREGATE	AGGREGATE DISCLOSURE													
	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	TOTAL AMOUNT	N/A
R & D	AGGREGATE DISCLOSURE											TOTAL AMOUNT		
	Research & Development Transfers of Value													

## **Methodological Notes**

### **Disclosure by Tillotts Pharma of payments to Italian healthcare professionals and healthcare organisations in 2018**

The Farmindustria Code on disclosure of transfers of value from companies to healthcare professionals and healthcare organisations mandates the public disclosure in 2019 of certain transfers of value made during 2018 to Italian healthcare professionals and healthcare organisations. The disclosure data will be published on the website of Tillotts Pharma, [www.tillotts.com](http://www.tillotts.com). The Farmindustria disclosure requirements are set forth in Section 5 of the Code of Conduct for the Pharmaceutical Industry.

The methodological notes below explain the data Tillotts Pharma has disclosed and how the data has been prepared, to assist the reader's understanding. Inclusion of this methodological note alongside the disclosure data is also mandated by Paragraph 5.10 of Section 5 to the Farmindustria Code.

#### **VAT**

VAT is excluded from all disclosures of transfer of value.

#### **Currency**

All disclosures are made in Euros (€). Where the original payment was made in another currency, the sum was converted to Euros based on the average annual exchange rate published by the European Central bank ([www.ecb.europa.eu](http://www.ecb.europa.eu)).

#### **Consolidated Disclosures of the Corporate Group and Cross-border Payments**

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. The 2018 disclosures represent payments by Tillotts Pharma AG, directly or indirectly.

#### **Aggregated Data**

Where permission to disclose transfers of value has been refused by individual healthcare professionals, or where permission was granted but then later revoked, all transfers of value made to them are disclosed in an aggregated fashion.

#### **Data Protection**

##### **Consent to disclose data**

In countries where it is required by applicable data protection laws, Tillotts has taken all reasonable steps to obtain consents from the HCPs, and HCOs, as applicable, to publicly disclose payments and other transfers of value. In accordance with EFPIA guidance, partial consents are not acceptable. If consent is not provided, the data will be reported on an aggregate level only.

##### **Consent collection and withdrawal**

Tillotts respects applicable data protection laws. If a stakeholder withdraws the provided consent, Tillotts will adjust the publication accordingly within a reasonable time.

*Data included*

The data disclosed by Tillotts Pharma is consistent with the requirements of the Farindustria Code. The data can be categorised as follows:

*Payment of consultants who provide services to Tillotts*

Disclosed data includes the payment of honoraria to Italian healthcare professionals who were paid in 2018 for services to Tillotts. Where applicable, the disclosure data also includes payment of reasonable expenses to such consultants in the delivery of their services, such as travel expenses or accommodation expenses.